GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives

References

• Stewart EA, Cookson CL, Gandolfo RA, et al. Epidemiology of uterine fibroids: a systematic review. BJOG: Int J Obstet Gy. 2017;124(10):1501–1512. doi: 10.1111/1471-0528.14640
   PubMed Web of Science ®Google Scholar
• Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. Int J Gynaecol Obstet. 2020;149(1):3–9. doi: 10.1002/ijgo.13102
   PubMed Web of Science ®Google Scholar
• Stewart EA, Laughlin-Tommaso SK, Catherino WH, et al. Uterine fibroids. Nat Rev Dis Primers. 2016;2(1):16043. doi: 10.1038/nrdp.2016.43
   PubMedGoogle Scholar
• Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016;22(6):665–686. doi: 10.1093/humupd/dmw023
   PubMed Web of Science ®Google Scholar
• Ciebiera M, Łoziński T. The role of magnetic resonance-guided focused ultrasound in fertility-sparing treatment of uterine fibroids-current perspectives. Ecancermedicalscience. 2020;14:1034. doi: 10.3332/ecancer.2020.1034
   PubMed Web of Science ®Google Scholar
• Ortmann O, Weiss JM, Diedrich K. Gonadotropin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action. Reprod Biomed Online. 2002;5:1–7. doi: 10.1016/S1472-6483(11)60210-1
   PubMedGoogle Scholar
• Yang Q, Ciebiera M, Bariani MV, et al. Comprehensive review of uterine fibroids: developmental origin, pathogenesis, and treatment. Endocr Rev. 2022;43(4):678–719. doi: 10.1210/endrev/bnab039
   PubMed Web of Science ®Google Scholar
• Marques P, Skorupskaite K, Rozario KS, et al. Physiology of GnRH and gonadotropin secretion. [Internet]. South Dartmouth (MA): MDText.com, Inc; 2000: Endotext; 2022. https://www.ncbi.nlm.nih.gov/books/NBK279070/ .
   Google Scholar
• Farris M, Bastianelli C, Rosato E, et al. Uterine fibroids: an update on current and emerging medical treatment options. Ther Clin Risk Manag. 2019;15:157–178. doi: 10.2147/TCRM.S147318
   PubMed Web of Science ®Google Scholar
• Coutinho EM, Boulanger GA, Goncalves MT. Regression of uterine leiomyomas after treatment with gestrinone, an antiestrogen, antiprogesterone. Am J Obstet Gynecol. 1986;155(4):761–767. doi: 10.1016/S0002-9378(86)80016-3
   PubMed Web of Science ®Google Scholar
• Vollenhoven BJ, Lawrence AS, Healy DL. Uterine fibroids: A clinical review. British J Obstet And Cynaecology. 1990;97(4):285–298. doi: 10.1111/j.1471-0528.1990.tb01804.x
   PubMedGoogle Scholar
• Stulberg DM. Ulipristal acetate works for fibroids, but its approval in the United States is threatened by safety concerns with long-term use. Evidence-Based Practice; 2020.
   Google Scholar
• Ciebiera M, Vitale SG, Ferrero S, et al. Vilaprisan, a new selective progesterone receptor modulator in uterine fibroid pharmacotherapy-will it really be a breakthrough? Curr Pharm Des. 2020;26(3):300–309. doi: 10.2174/1381612826666200127092208
   PubMed Web of Science ®Google Scholar
• Lee MJ, Yun BS, Seong SJ, et al. Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist. Obstet Gynecol Sci. 2017;60(1):69. doi: 10.5468/ogs.2017.60.1.69
   PubMedGoogle Scholar
• de Milliano I, Huirne JAF, Thurkow AL, et al. Ulipristal acetate vs gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy (MYOMEX trial): Short-term results of a double-blind randomized controlled trial. Acta Obstet Gynecol Scand. 2020;99(1):89–98. doi: 10.1111/aogs.13713
   PubMed Web of Science ®Google Scholar
• Madueke-Laveaux OS, Ciebiera M, Al-Hendy A, GnRH analogs for the treatment of heavy menstrual bleeding associated with uterine fibroids. F&S Reports, 2022.
   Google Scholar
• Golan A. GnRH analogues in the treatment of uterine fibroids. Hum Reprod. 1996;11(Suppl 3):33–41. doi:10.1093/humrep/11.suppl_3.33
   PubMed Web of Science ®Google Scholar
• Lewis TD, Malik M, Britten J, et al. A comprehensive review of the Pharmacologic management of uterine leiomyoma. Bio Med Res Int. 2018;2018:1–11. doi: 10.1155/2018/2414609
   Google Scholar
• Moroni RM, Martins WP, Ferriani RA, et al. Add-back therapy with GnRH analogues for uterine fibroids. Cochrane Database Syst Rev. 2015;2015(3):Cd010854. doi: 10.1002/14651858.CD010854.pub2
   PubMedGoogle Scholar
• Schally AV, Comaru-Schally AM. Mode of action of LHRH analogs. 6th ed. Hamilton, ON: Holland-Frei Cancer Medicine; 2003. https://www.ncbi.nlm.nih.gov/books/NBK12517/
   Google Scholar
• Sinai Talaulikar V, Belli AM, Manyonda I. GnRH agonists: do they have a place in the modern management of fibroid disease? J Obstet Gynaecol India. 2012;62(5):506–510. doi: 10.1007/s13224-012-0206-0
   PubMedGoogle Scholar
• Munro MG, Critchley HO, Broder MS, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3–13. doi: 10.1016/j.ijgo.2010.11.011
   PubMed Web of Science ®Google Scholar
• Donnez J. Uterine fibroids and progestogen treatment: lack of evidence of its efficacy: a review. J Clin Med. 2020;9(12):3948. doi: 10.3390/jcm9123948
   PubMed Web of Science ®Google Scholar
• Regidor PA, Regidor M, Schmidt M, et al. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis. Gynecol Endocrinol. 2001;15(3):202–209. doi: 10.1080/gye.15.3.202.209
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Kubba A, Caetano C, et al. Thirty years of mirena: a story of innovation and change in women’s healthcare. Acta Obstet Gynecol Scand. 2021;100(4):614–618. doi: 10.1111/aogs.14110
   PubMed Web of Science ®Google Scholar
• Evangelisti G, Barra F, Perrone U, et al. Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids. Expert Opin Drug Metab Toxicol. 2022;18(7–8):441–457. doi: 10.1080/17425255.2022.2113381
   PubMed Web of Science ®Google Scholar
• Ortmann O, Weiss JM, Diedrich K. Gonadotropin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action. Reprod Biomed Online. 2002;5(Suppl 1):1–7. doi: 10.1016/S1472-6483(11)60210-1
   PubMedGoogle Scholar
• Hodgson R, Bhave Chittawar P, Farquhar C. GnRH agonists for uterine fibroids. Cochrane Database Syst Rev. 2017;2017(10). doi: 10.1002/14651858.CD012846
   Google Scholar
• Palomba S, Falbo A, Russo T, et al. GnRH analogs for the treatment of symptomatic uterine leiomyomas. Gynecol Surg. 2005;2(1):7–13. doi: 10.1007/s10397-004-0078-0
   Google Scholar
• Magon N. Gonadotropin releasing hormone agonists: expanding vistas. Indian J Endocr Metab. 2011;15(4):261–267. doi: 10.4103/2230-8210.85575
   PubMedGoogle Scholar
• Wang P-H, Lee WL, Cheng MH, et al. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas. Taiwanese J Obstetrics Gynecol. 2009;48(2):133–137. doi: 10.1016/S1028-4559(09)60273-4
   PubMed Web of Science ®Google Scholar
• Bianchi G, Costantini S, Anserini P, et al. Effects of gonadotropin-releasing hormone agonist on uterine fibroids and bone density. Maturitas. 1989;11(3):179–185. doi: 10.1016/0378-5122(89)90209-0
   PubMed Web of Science ®Google Scholar
• Miller RM, Frank RA. Zoladex (goserelin) in the treatment of benign gynaecological disorders: an overview of safety and efficacy. Br J Obstet Gynaecol. 1992;99(Suppl 7):37–41. doi: 10.1111/j.1471-0528.1992.tb13539.x
   PubMedGoogle Scholar
• Muneyyirci-Delale O, Richard-Davis G, Morris T, et al. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a phase III, randomized, multicenter, double-blind, controlled trial. Clin Ther. 2007;29(8):1682–1691. doi: 10.1016/j.clinthera.2007.08.024
   PubMed Web of Science ®Google Scholar
• Fedele L, Bianchi S, Baglioni A, et al. Intranasal buserelin versus surgery in the treatment of uterine leiomyomata: long-term follow-up. Eur J Obstet Gynecol Reprod Biol. 1991;38(1):53–57. doi: 10.1016/0028-2243(91)90207-2
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Kobori H, Kikuchi I, et al. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis. J Obstet Gynaecol Res. 2000;26(5):325–331. doi: 10.1111/j.1447-0756.2000.tb01334.x
   PubMedGoogle Scholar
• Lim SS, Sockalingam JK, Tan PC. Goserelin versus leuprolide before hysterectomy for uterine fibroids. Int J Gynaecol Obstet. 2008;101(2):178–183. doi: 10.1016/j.ijgo.2007.10.020
   PubMed Web of Science ®Google Scholar
• Mohammed NH, Al-Taie A, Albasry Z. Evaluation of goserelin effectiveness based on assessment of inflammatory cytokines and symptoms in uterine leiomyoma. Int J Clin Pharm. 2020;42(3):931–937. doi: 10.1007/s11096-020-01030-3
   PubMed Web of Science ®Google Scholar
• Ciebiera M, Włodarczyk M, Zgliczyńska M, et al. The role of tumor necrosis factor α in the biology of uterine fibroids and the related symptoms. Int J Mol Sci. 2018;19(12):3869. doi: 10.3390/ijms19123869
   PubMed Web of Science ®Google Scholar
• Schriock ED. GnRH agonists. Clin Obstet Gynecol. 1989;32(3):550–563. doi:10.1097/00003081-198909000-00019
   PubMed Web of Science ®Google Scholar
• Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, Clinical a pnd Research Information on Drug-Induced Liver Injury. LiverTox, 2012.
   Google Scholar
• Howles CM. The place of gonadotropin-releasing hormone antagonists in reproductive medicine. Reprod Biomed Online. 2002;4(Suppl 3):64–71. doi: 10.1016/S1472-6483(12)60120-5
   PubMedGoogle Scholar
• Dal Prato L, Borini A. Use of antagonists in ovarian stimulation protocols. Reprod Biomed Online. 2005;10(3):330–338. doi: 10.1016/S1472-6483(10)61792-0
   PubMed Web of Science ®Google Scholar
• Maggi R, Cariboni AM, Marelli MM, et al. GnRH and GnRH receptors in the pathophysiology of the human female reproductive system. Hum Reprod Update. 2016;22(3):358–381. doi: 10.1093/humupd/dmv059
   PubMed Web of Science ®Google Scholar
• Engmann L, DiLuigi A, Schmidt D, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89(1):84–91. doi: 10.1016/j.fertnstert.2007.02.002
   PubMed Web of Science ®Google Scholar
• Olivennes F. The use of gonadotropin-releasing hormone antagonist in ovarian stimulation. Clin Obstet Gynecol. 2006;49(1):12–22. doi: 10.1097/01.grf.0000197520.53682.32
   PubMed Web of Science ®Google Scholar
• Tur-Kaspa I, Ezcurra D. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology. Expert Opin Drug Metab Toxicol. 2009;5(10):1323–1336. doi: 10.1517/17425250903279969
   PubMed Web of Science ®Google Scholar
• Ludwig M, Katalinic A, Diedrich K. Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-Analysis Arch Gynecol Obstet. 2001;265(4):175–182. doi: 10.1007/s00404-001-0267-2
   PubMedGoogle Scholar
• Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotropin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011;5:Cd001750.
   PubMed Web of Science ®Google Scholar
• Seelig AS, Al-Hasani S, Katalinic A, et al. Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle. Fertil Steril. 2002;77(3):472–475. doi: 10.1016/S0015-0282(01)03008-4
   PubMed Web of Science ®Google Scholar
• Nikolettos N, Al-Hasani S, Felberbaum R, et al. Comparison of cryopreservation outcome with human pronuclear stage oocytes obtained by the GnRH antagonist, cetrorelix, and GnRH agonists. Eur J Obstet Gynecol Reprod Biol. 2000;93(1):91–95. doi: 10.1016/S0301-2115(99)00294-8
   PubMed Web of Science ®Google Scholar
• Vlahos NF, Bankowski BJ, Zacur HA, et al. An oocyte donation protocol using the GnRH antagonist ganirelix acetate, does not compromise embryo quality and is associated with high pregnancy rates. Arch Gynecol Obstet. 2005;272(1):1–6. doi: 10.1007/s00404-005-0726-2
   PubMedGoogle Scholar
• Kolibianakis EM, Collins J, Tarlatzis BC, et al. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update. 2006;12(6):651–671. doi: 10.1093/humupd/dml038
   PubMed Web of Science ®Google Scholar
• Gillies PS, Faulds D, Barman BJA, et al. Ganirelix. Ganirelix Drugs. 2000;59(1):107–111. doi: 10.2165/00003495-200059010-00007
   PubMed Web of Science ®Google Scholar
• Oberyé JJ, Mannaerts BM, Kleijn HJ, et al. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertil Steril. 1999;72(6):1001–1005. doi: 10.1016/S0015-0282(99)00413-6
   PubMed Web of Science ®Google Scholar
• Borm G, Mannaerts B. Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The Eur Orgalutran Study Group Hum Reprod. 2000;15(7):1490–1498. doi: 10.1093/humrep/15.7.1490
   PubMed Web of Science ®Google Scholar
• European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod. 2001;16(4):644–651. doi: 10.1093/humrep/16.4.644
   PubMed Web of Science ®Google Scholar
• Fluker M, Grifo J, Leader A, et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 2001;75(1):38–45. doi: 10.1016/S0015-0282(00)01638-1
   PubMed Web of Science ®Google Scholar
• Olivennes F, Mannaerts B, Struijs M, et al. Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report. Hum Reprod. 2001;16(8):1588–1591. doi: 10.1093/humrep/16.8.1588
   PubMed Web of Science ®Google Scholar
• Rein MS, Friedman AJ, Stuart JM, et al. Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate. Fertil Steril. 1990;53(6):1018–1023. doi: 10.1016/S0015-0282(16)53578-X
   PubMed Web of Science ®Google Scholar
• Wiznitzer A, Marbach M, Hazum E, et al. Gonadotropin-releasing hormone specific binding sites in uterine leiomyomata. Biochem Biophys Res Commun. 1988;152(3):1326–1331. doi: 10.1016/S0006-291X(88)80430-3
   PubMed Web of Science ®Google Scholar
• Engel JB, Audebert A, Frydman R, et al. Presurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: a double-blind, placebo-controlled multicenter study. Eur J Obstet Gynecol Reprod Biol. 2007;134(2):225–232. doi: 10.1016/j.ejogrb.2006.07.018
   PubMed Web of Science ®Google Scholar
• Flierman PA, Oberyé JJ, van der Hulst VP, et al. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix. BJOG. 2005;112(5):638–642. doi: 10.1111/j.1471-0528.2004.00504.x
   PubMed Web of Science ®Google Scholar
• Matta WH, Shaw RW, Hesp R, et al. Hypogonadism induced by luteinising hormone releasing hormone agonist analogues: effects on bone density in premenopausal women. Br Med J (Clin Res Ed). 1987;294(6586):1523–1524. doi: 10.1136/bmj.294.6586.1523
   PubMedGoogle Scholar
• Coddington CC, Collins RL, Shawker TH, et al. Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri. Fertil Steril. 1986;45(5):624–629. doi: 10.1016/S0015-0282(16)49332-5
   PubMed Web of Science ®Google Scholar
• Felberbaum RE, Germer U, Ludwig M, et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotropin releasing hormone antagonist cetrorelix. Hum Reprod. 1998;13(6):1660–1668. doi: 10.1093/humrep/13.6.1660
   PubMed Web of Science ®Google Scholar
• Chegini N, Rong H, Dou Q, et al. Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomyomata and the direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro. J Clin Endocrinol Metab. 1996;81(9):3215–3221. doi: 10.1210/jc.81.9.3215
   PubMed Web of Science ®Google Scholar
• Parker JD, Malik M, Catherino WH. Human myometrium and leiomyomas express gonadotropin-releasing hormone 2 and gonadotropin-releasing hormone 2 receptor. Fertil Steril. 2007;88(1):39–46. doi: 10.1016/j.fertnstert.2006.11.098
   PubMed Web of Science ®Google Scholar
• Kwon JY, Park KH, Park YN, et al. Effect of cetrorelix acetate on apoptosis and apoptosis regulatory factors in cultured uterine leiomyoma cells. Fertil Steril. 2005;84(5):1526–1528. doi: 10.1016/j.fertnstert.2005.06.022
   PubMed Web of Science ®Google Scholar
• Sadow TF, Rubin RT. Effects of hypothalamic peptides on the aging brain. Psychoneuroendocrinology. 1992;17(4):293–314. doi:10.1016/0306-4530(92)90036-7
   PubMed Web of Science ®Google Scholar
• Chegini N, Ma C, Tang XM, et al. Effects of GnRH analogues, ‘add-back’ steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression. Mol Hum Reprod. 2002;8(12):1071–1078. doi: 10.1093/molehr/8.12.1071
   PubMed Web of Science ®Google Scholar
• Wright D, Kim JW, Lindsay H, et al. A review of GnRH antagonists as treatment for abnormal uterine bleeding-leiomyoma (AUB-L) and their influence on the readiness of service members. Mil Med; 2022.Mar 28:usac078. doi: 10.1093/milmed/usac078. Epub ahead of print. PMID: 35348746.
   Google Scholar
• Lamb YN. Elagolix: First Global approval. Drugs. 2018;78(14):1501–1508. doi: 10.1007/s40265-018-0977-4
   PubMed Web of Science ®Google Scholar
• Drugs and Lactation Database (LactMed®). Elagolix. Elagolix, 2019. [cited 2019 Feb 7]. Bethesda (MD): National Institute of Child Health and Human Development; 2006. https://www.ncbi.nlm.nih.gov/books/NBK525496/
   Google Scholar
• Lamb YN. Correction to: elagolix: first global approval. Drugs. 2018;78(17):1855–1855. doi:10.1007/s40265-018-1014-3
   PubMed Web of Science ®Google Scholar
• Archer DF, Stewart EA, Jain RI, et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertil Steril. 2017;108(1):152–160.e4. doi: 10.1016/j.fertnstert.2017.05.006
   PubMed Web of Science ®Google Scholar
• Carr BR, Stewart EA, Archer DF, et al. Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2018;132(5):1252–1264. doi: 10.1097/AOG.0000000000002933
   PubMed Web of Science ®Google Scholar
• Schlaff WD, Ackerman RT, Al-Hendy A, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382(4):328–340. doi: 10.1056/NEJMoa1904351
   PubMed Web of Science ®Google Scholar
• Simon JA, Al-Hendy A, Archer DF, et al. Elagolix treatment for up to 12 months in women with heavy menstrual bleeding and uterine leiomyomas. Obstet & Gynecol. 2020;135(6):1313–1326. doi: 10.1097/AOG.0000000000003869
   PubMed Web of Science ®Google Scholar
• Al-Hendy A, Bradley L, Owens CD, et al. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol. 2021;224(1):.e72.1–.e72.50. doi: 10.1016/j.ajog.2020.07.032
   Web of Science ®Google Scholar
• Stewart EA, Archer DF, Owens CD, et al. Reduction of heavy menstrual bleeding in women not designated as responders to elagolix plus add back therapy for uterine fibroids. J Womens Health (Larchmt). 2022;31(5):698–705. doi: 10.1089/jwh.2021.0152
   PubMed Web of Science ®Google Scholar
• Telek SB, Gurbuz Z, Kalafat E, et al. Oral gonadotropin-releasing hormone antagonists in the treatment of uterine myomas: a systematic review and network meta-analysis of efficacy parameters and adverse effects. J Minim Invasive Gynecol. 2022;29(5):613–625. doi: 10.1016/j.jmig.2021.12.011
   PubMed Web of Science ®Google Scholar
• Beck D, Winzenborg I, Liu M, et al. Population Pharmacokinetics of elagolix in combination with Low-dose estradiol/norethindrone acetate in women with uterine fibroids. Clin Pharmacokinet. 2022;61(4):577–587. doi: 10.1007/s40262-021-01096-w
   PubMed Web of Science ®Google Scholar
• Shebley M, Polepally AR, Nader A, et al. Clinical Pharmacology of elagolix: an oral gonadotropin-releasing hormone Receptor antagonist for endometriosis. Clin Pharmacokinet. 2020;59(3):297–309. doi: 10.1007/s40262-019-00840-7
   PubMed Web of Science ®Google Scholar
• Beck D, Winzenborg I, Gao W, et al. Interdisciplinary model-informed drug development for extending duration of elagolix treatment in patients with uterine fibroids. Br J Clin Pharmacol. 2022;88(12):5257–5268. doi: 10.1111/bcp.15440
   PubMed Web of Science ®Google Scholar
• Nader A, Mostafa NM, Ali F, et al. Drug-drug interaction studies of elagolix with oral and transdermal low-dose hormonal add-back therapy. Clin Pharmacokinet. 2021;60(1):133–143. doi: 10.1007/s40262-020-00921-y
   PubMed Web of Science ®Google Scholar
• Rocca ML, Palumbo AR, Lico D, et al. Relugolix for the treatment of uterine fibroids. Expert Opin Pharmacother. 2020;21(14):1667–1674. doi: 10.1080/14656566.2020.1787988
   PubMed Web of Science ®Google Scholar
• Al-Hendy A, Lukes AS, Poindexter AN, 3rd. et al. Long-term relugolix combination therapy for symptomatic uterine leiomyomas. Obstet Gynecol. 2022;140(6):920–930. doi: 10.1097/AOG.0000000000004988
   PubMed Web of Science ®Google Scholar
• Osuga Y, Enya K, Kudou K, et al. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: A randomized controlled trial. Obstet Gynecol. 2019;133(3):423–433. doi: 10.1097/AOG.0000000000003141
   PubMed Web of Science ®Google Scholar
• Niaz R, Saeed M, Khan H, et al. Efficacy and safety of oral GnRh antagonists in patients with uterine fibroids: a systematic review. J Obstet Gynaecol Can. 2022;44(12):1279–1288. doi: 10.1016/j.jogc.2022.10.012
   PubMed Web of Science ®Google Scholar
• Al-Hendy A, Lukes AS, Poindexter AN, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med. 2021;384(7):630–642. 3rd. doi: 10.1056/NEJMoa2008283
   PubMed Web of Science ®Google Scholar
• Syed YY. Relugolix/Estradiol/Norethisterone (norethindrone) acetate: A review in symptomatic uterine fibroids. Drugs. 2022;82(15):1549–1556. doi:10.1007/s40265-022-01790-4
   PubMed Web of Science ®Google Scholar
• Osuga Y, Enya K, Kudou K, et al. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women. Fertil Steril. 2019;112(5):922–9 e2. doi: 10.1016/j.fertnstert.2019.07.013
   PubMed Web of Science ®Google Scholar
• Hoshiai H, Seki Y, Kusumoto T, et al. Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial. BMC Women's Health. 2021;21(1):375. doi: 10.1186/s12905-021-01475-2
   PubMed Web of Science ®Google Scholar
• Stewart EA, Lukes AS, Venturella R, et al. Relugolix combination therapy for uterine leiomyoma–associated pain in the LIBERTY randomized trials. Am J Obstet Gynecol. 2022;139(6):1070–1081. doi: 10.1097/AOG.0000000000004787
   Google Scholar
• Stewart EA, Lukes AS, Venturella R, et al. Relugolix combination therapy for uterine leiomyoma-associated pain in the LIBERTY randomized trials. Obstet Gynecol. 2022;139(6):1070–1081. doi: 10.1097/AOG.0000000000004787
   PubMed Web of Science ®Google Scholar
• Takeda A. Short-term administration of oral relugolix before single-port laparoscopic-assisted vaginal hysterectomy for symptomatic uterine myomas: a retrospective comparative study with leuprorelin injection. J Obstet Gynaecol Res. 2022;48(7):1921–1929. doi:10.1111/jog.15269
   PubMed Web of Science ®Google Scholar
• Keam SJ. Linzagolix: First approval. Drugs. 2022;82(12):1317–1325. doi: 10.1007/s40265-022-01753-9
   PubMed Web of Science ®Google Scholar
• Ali M, Raslan M, Ciebiera M, et al. Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids. Expert Opin Drug Saf. 2022;21(4):477–486. doi: 10.1080/14740338.2022.1989409
   PubMed Web of Science ®Google Scholar
• Rovelli RJ, Cieri-Hutcherson NE, Hutcherson TC Systematic review of oral pharmacotherapeutic options for the management of uterine fibroids. J Am Pharm Assoc. 2003;62(3):674–682.e5. 2022. doi: 10.1016/j.japh.2022.02.004
   Google Scholar
• Donnez J, Taylor HS, Stewart EA, et al. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. Lancet. 2022;400(10356):896–907. doi: 10.1016/S0140-6736(22)01475-1
   PubMed Web of Science ®Google Scholar
• Beatty MN. The levonorgestrel-releasing intrauterine system: Safety, efficacy and patient acceptability. Ther Clin Risk Manag. 2009;5(3):561–574. doi: 10.2147/TCRM.S5624
   PubMedGoogle Scholar
• Salas A, García-García P, Díaz-Rodríguez P, et al. New local ganirelix sustained release therapy for uterine leiomyoma. Evaluation in a preclinical organ model. Biomed Pharmacother. 2022;156:113909. doi: 10.1016/j.biopha.2022.113909
   PubMed Web of Science ®Google Scholar
• Ali M, Laknaur A, Shaheen SM, et al. Vitamin D synergizes the antiproliferative, apoptotic, antifibrotic and anti-inflammatory effects of ulipristal acetate against human uterine fibroids. Fertil Sterility. 2017;108(3):e66. doi: 10.1016/j.fertnstert.2017.07.208
   Web of Science ®Google Scholar
• Ciebiera M, Męczekalski B, Łukaszuk K, et al. Potential synergism between ulipristal acetate and vitamin D3 in uterine fibroid pharmacotherapy - 2 case studies. Gynecol Endocrinol. 2019;35(6):473–477. doi: 10.1080/09513590.2018.1550062
   PubMed Web of Science ®Google Scholar
• Porcaro G, Santamaria A, Giordano D, et al. Vitamin D plus epigallocatechin gallate: a novel promising approach for uterine myomas. Eur Rev Med Pharmacol Sci. 2020;24(6):3344–3351. doi: 10.26355/eurrev_202003_20702
   PubMed Web of Science ®Google Scholar
• Miriello D, Galanti F, Cignini P, et al. Uterine fibroids treatment: do we have new valid alternative? Experiencing the combination of vitamin D plus epigallocatechin gallate in childbearing age affected women. Eur Rev Med Pharmacol Sci. 2021;25(7):2843–2851. doi: 10.26355/eurrev_202104_25537
   PubMed Web of Science ®Google Scholar
• Vahdat M, Kashanian M, Ghaziani N, et al. Evaluation of the effects of cabergoline (Dostinex) on women with symptomatic myomatous uterus: a randomized trial. Eur J Obstet Gynecol Reprod Biol. 2016;206:74–78. doi: 10.1016/j.ejogrb.2016.08.013
   PubMed Web of Science ®Google Scholar
• Smart OC, Hindley JT, Regan L, et al. Gonadotrophin-releasing hormone and magnetic-resonance-guided ultrasound surgery for uterine leiomyomata. Obstet Gynecol. 2006;108(1):49–54. doi: 10.1097/01.AOG.0000222381.94325.4f
   PubMed Web of Science ®Google Scholar
• Łoziński T, Filipowska J, Gurynowicz G, et al. The effect of high-intensity focused ultrasound guided by magnetic resonance therapy on obstetrical outcomes in patients with uterine fibroids – experiences from the main Polish center and a review of current data. Int J Hyperthermia. 2019;36(1):581–589. doi: 10.1080/02656736.2019.1616117
   Web of Science ®Google Scholar